Q-omics provides the consensus-scored PRELID1P4 profile across patient tissues and cancer cell-line models. PRELID1P4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRELID1P4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PRELID1P4 RNA expression shows 14,824 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where PRELID1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID1P4 survival associations across molecular data types. PRELID1P4 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID1P4 RNA expression–survival associations across cancer types. High PRELID1P4 expression shows unfavorable associations in KIRC, STAD, LGG, ACC and UVM, but favorable associations in MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRELID1P4 RNA expression.
This table summarizes PRELID1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID1P4 shows lower tumor expression in UCEC and KICH and higher tumor expression in KIRC, BRCA, LIHC and CHOL. The KIRC box plot shows higher PRELID1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.428, t-test p < 0.001).
This table shows molecular features associated with PRELID1P4 in patient tissues and cancer cell lines. In patient samples, PRELID1P4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
